BIOMAT Database Logo BIOMAT Database Logo

Probiotic Escherichia coli NISSLE 1917 for inflammatory bowel disease applications. 2022

Zejing Zhao, and Shumin Xu, and Wangyang Zhang, and Danjun Wu, and Gensheng Yang
College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, China. danjunwu@zjut.edu.cn.

Escherichia coli NISSLE 1917 (EcN) is a Gram-negative strain with many prominent probiotic properties in the treatment of intestinal diseases such as diarrhea and inflammatory bowel disease (IBD), in particular ulcerative colitis. EcN not only exhibits antagonistic effects on a variety of intestinal pathogenic bacteria, but also regulates the secretion of immune factors in vivo and enhances the ability of host immunity. In this review, the mechanisms of EcN in the remission of inflammatory bowel disease are proposed and recent advances on the functionalized EcN are compiled to provide novel therapeutic strategies for the prevention and treatment of IBD.

UI MeSH Term Description Entries
D003093 Colitis, Ulcerative Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN. Colitis Gravis,Idiopathic Proctocolitis,Inflammatory Bowel Disease, Ulcerative Colitis Type,Ulcerative Colitis
D003967 Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight. Diarrheas
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D004927 Escherichia coli Infections Infections with bacteria of the species ESCHERICHIA COLI. E coli Infections,E. coli Infection,Infections, E coli,Infections, Escherichia coli,E coli Infection,E. coli Infections,Escherichia coli Infection,Infection, E coli,Infection, E. coli,Infection, Escherichia coli
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D019936 Probiotics Live microbial DIETARY SUPPLEMENTS which beneficially affect the host animal by improving its intestinal microbial balance. Antibiotics and other related compounds are not included in this definition. In humans, lactobacilli are commonly used as probiotics, either as single species or in mixed culture with other bacteria. Other genera that have been used are bifidobacteria and streptococci. (J. Nutr. 1995;125:1401-12) Probiotic

Related Publications

Zejing Zhao, and Shumin Xu, and Wangyang Zhang, and Danjun Wu, and Gensheng Yang
Escherichia coli Nissle 1917 ghosts alleviate inflammatory bowel disease in zebrafish.
September 2023, Life sciences,
Zejing Zhao, and Shumin Xu, and Wangyang Zhang, and Danjun Wu, and Gensheng Yang
Genetic engineering of probiotic Escherichia coli Nissle 1917 for clinical application.
October 2016, Applied microbiology and biotechnology,
Zejing Zhao, and Shumin Xu, and Wangyang Zhang, and Danjun Wu, and Gensheng Yang
Sever sepsis after probiotic treatment with Escherichia coli NISSLE 1917.
February 2010, The Pediatric infectious disease journal,
Zejing Zhao, and Shumin Xu, and Wangyang Zhang, and Danjun Wu, and Gensheng Yang
Clinical use of E. coli Nissle 1917 in inflammatory bowel disease.
July 2008, Inflammatory bowel diseases,
Zejing Zhao, and Shumin Xu, and Wangyang Zhang, and Danjun Wu, and Gensheng Yang
Expanding the toolbox of probiotic Escherichia coli Nissle 1917 for synthetic biology.
January 2024, Biotechnology journal,
Zejing Zhao, and Shumin Xu, and Wangyang Zhang, and Danjun Wu, and Gensheng Yang
[Elafin-expressing probiotic Escherichia coli Nissle 1917 protects against experimental colitis].
December 2021, Zhonghua yi xue za zhi,
Zejing Zhao, and Shumin Xu, and Wangyang Zhang, and Danjun Wu, and Gensheng Yang
Escherichia coli Nissle 1917 for probiotic use in piglets: evidence for intestinal colonization.
November 2009, Journal of applied microbiology,
Zejing Zhao, and Shumin Xu, and Wangyang Zhang, and Danjun Wu, and Gensheng Yang
Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity.
December 2007, PloS one,
Zejing Zhao, and Shumin Xu, and Wangyang Zhang, and Danjun Wu, and Gensheng Yang
Probiotic Escherichia coli Nissle 1917 inhibits bacterial persisters that survive fluoroquinolone treatment.
June 2022, Journal of applied microbiology,
Zejing Zhao, and Shumin Xu, and Wangyang Zhang, and Danjun Wu, and Gensheng Yang
Probiotic Escherichia coli strain Nissle 1917 outcompetes intestinal pathogens during biofilm formation.
April 2010, Journal of medical microbiology,
Copied contents to your clipboard!